EYE National Vision Holdings, Inc.
Ophthalmic Goods · Nasdaq · SEC CIK 1710155 · Fiscal year ends 01/02
Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY2,964.0%
TTM EPS YoY2,833.3%
Revenue 3-yr CAGR4.5%
Net income 3-yr CAGR—
Margins
Gross margin58.8%
Operating margin5.1%
Net margin3.2%
FCF margin3.3%
EBITDA margin9.6%
Returns
ROE7.5%
ROA3.3%
ROIC (approx.)7.2%
Asset turnover1.04x
Leverage & solvency
Liabilities / assets55.0%
Debt / equity0.25x
Current ratio0.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.24x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-01-03 | FY20242024-12-28 | FY20232023-12-30 | FY20222022-12-31 | FY20212022-01-01 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.99B | $1.82B | $1.76B | $1.64B | $2.08B |
| Cost of revenue | $819.47M | $764.06M | $734.65M | $667.66M | $904.78M |
| Gross profit | $1.17B | $1.06B | $1.02B | $977.01M | $1.17B |
| SG&A expense | $1.02B | $938.52M | $904.76M | $832.61M | $900.80M |
| Operating income | $58.83M | -$10.36M | $24.49M | $52.77M | $174.94M |
| Interest expense | — | — | — | — | $25.61M |
| Pretax income | $41.68M | -$25.68M | $9.55M | $52.30M | $149.32M |
| Income tax | $12.08M | $1.48M | $6.01M | $15.54M | $21.08M |
| Net income | $29.60M | -$28.50M | -$65.90M | $42.12M | $128.24M |
| EBITDA | $149.98M | $80.99M | $114.36M | $141.46M | $272.03M |
| EPS (basic) | 0.37 | -0.36 | -0.84 | 0.53 | 1.57 |
| EPS (diluted) | 0.37 | -0.36 | -0.84 | 0.52 | 1.43 |
| Weighted avg. shares (diluted) | 80.58M | 78.59M | 78.60M | 80.30M | 96.13M |
| Balance sheet | |||||
| Cash & equivalents | $38.71M | $75.24M | $149.90M | $230.62M | $306.88M |
| Receivables | $57.32M | $49.94M | $86.85M | $79.89M | $55.70M |
| Inventory | $89.32M | $93.92M | $119.91M | $123.16M | $123.67M |
| Current assets | $225.72M | $249.83M | $396.67M | $473.84M | $514.58M |
| PP&E, net | $344.62M | $362.18M | $360.19M | $359.77M | $346.44M |
| Goodwill | $700.64M | $698.30M | $717.54M | $777.61M | $777.61M |
| Intangibles | $7.55M | $8.27M | $20.17M | $34.67M | $42.02M |
| Total assets | $1.98B | $2.01B | $2.17B | $2.29B | $2.29B |
| Current liabilities | $412.41M | $468.27M | $397.70M | $344.26M | $343.80M |
| Short-term debt | $13.25M | $98.02M | $7.50M | $0 | $0 |
| Long-term debt | $223.24M | $239.15M | $437.68M | $546.23M | $543.57M |
| Total debt | $236.49M | $337.17M | $445.18M | $546.23M | $543.57M |
| Total liabilities | $1.11B | $1.19B | $1.34B | $1.39B | $1.37B |
| Shareholders' equity | $869.53M | $816.33M | $829.42M | $901.11M | $925.98M |
| Net debt | $197.78M | $261.93M | $295.29M | $315.61M | $236.69M |
| Shares outstanding | 79.42M | 78.78M | 78.31M | 78.99M | 81.41M |
| Cash flow statement | |||||
| Operating cash flow | $146.29M | $133.65M | $173.03M | $119.20M | $258.94M |
| Capital expenditure | $72.84M | $95.50M | $114.77M | $113.55M | $95.52M |
| Free cash flow | $73.45M | $38.14M | $58.26M | $5.65M | $163.42M |
| Investing cash flow | -$76.61M | -$96.09M | -$115.82M | -$110.89M | -$92.90M |
| Financing cash flow | -$104.62M | -$113.34M | -$136.81M | -$84.56M | -$234.32M |
| Depreciation & amortization | $91.15M | $91.35M | $89.87M | $88.69M | $97.09M |
| Stock-based compensation | $23.69M | $16.71M | $20.17M | $13.51M | $14.89M |
| Share buybacks | $3.21M | $3.09M | $28.41M | $84.39M | $73.30M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.